NCT00233532已完成4 期
A Prospective, Open-Label Study to Evaluate the Effect of an Escalating Dose Regimen of Trandolapril on Blood Pressure in Treatment-Naïve and Concurrently Treated Hypertensive Patients (TRAIL)
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Abbott
- 入组人数
- 2,000
- 主要终点
- Effectiveness of escalating dose regimen of trandolapril in controlling blood pressure
研究概览
简要总结
The TRAIL study was conducted to examine the effects of escalating doses of an ACE inhibitor, trandolapril, on lowering blood pressure in Stage 1-2 hypertensive patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Stage 1 or 2 Hypertension
排除标准
- •Uncontrolled diabetes
- •Subject has a hypersensitivity to ACE inhibitor
研究组 & 干预措施
1
Other
干预措施: Trandolapril (Drug)
2
Other
干预措施: Trandolapril (Drug)
3
Other
干预措施: Trandolapril (Drug)
结局指标
主要结局
Effectiveness of escalating dose regimen of trandolapril in controlling blood pressure
时间窗: 14 weeks
次要结局
- Changes in blood pressure, safety.(14 and 26 weeks)
- BP mmHg incremental and absolute change(14 and 26 weeks)
- Adverse events(Throughout 26 weeks)
研究者
相似试验
已完成
2 期
Long Term Treatment Effect of the Safety, Tolerability and Efficacy of AAT in Type 1 DiabetesBeta Cell PreservationType 1 DiabetesNCT01661192Rabin Medical Center12
已完成
1 期
Safety,Tolerability and MTD KA2507 (HDAC6 Inhibitor) in Patients With Solid TumoursSolid Tumor, AdultNCT03008018Karus Therapeutics Limited20
已完成
1 期
A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.Advanced Solid TumorsNCT03545971Innovent Biologics (Suzhou) Co. Ltd.53
终止
1 期
A Study of Varlilumab and Atezolizumab in Patients With Advanced CancerCarcinoma, Renal CellKidney DiseasesKidney NeoplasmsUrogenital NeoplasmsUrologic DiseasesUrologic NeoplasmsNeoplasms by Histologic TypeNeoplasmsClear-cell Metastatic Renal Cell CarcinomaTriple Negative Breast CancerHead and Neck CancerMelanomaBladder CancerNon-small Cell Lung CancerNCT02543645Celldex Therapeutics18
已完成
1 期
A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid TumorsNeoplasmsNCT02410512Genentech, Inc.610